The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib as the third line therapy for patients with advanced gastric cancer.
Stomach Neoplasms
BIOLOGICAL: Cytokine-Induced Killer Cells|DRUG: Apatinib
Overall Survival(OS), 3 months
Disease-free survival, 3 months
Adverse events, 1 months
400 patients with stage Ⅳ Gastric Cancer,who had received surgery and chemotherapy,will be randomly divided into group A（receive Apatinib and CIK treatment ) or group B（just receive Apatinib),and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of CIK treatment (every 1 year) and Apatinib (continuous).Patients in group B will receive only Apatinib (continuous) .